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Proximal Endovascular Occlusion
for Carotid Artery Stenting
Results From a Prospective Registry of 1,300 Patients
Eugenio Stabile, MD, PHD, Luigi Salemme, MD, Giovanni Sorropago, MD, Tullio Tesorio, MD,
Wail Nammas, MD, Marianna Miranda, MD, Grigore Popusoi, MD, Angelo Cioppa, MD,
Vittorio Ambrosini, MD, Linda Cota, MD, Giampaolo Petroni, MD, Giovanni Della Pietra, MD,
Angelo Ausania, MD, Arturo Fontanelli, MD, Giancarlo Biamino, MD, Paolo Rubino, MD
Mercogliano, Italy
Objectives This single-center registry presents the results of proximal endovascular occlusion (PEO) use in an unselected
patient population.
Background In published multicenter registries, the use of PEO for carotid artery stenting (CAS) has been demonstrated to be
safe and efficient in patient populations selected for anatomical and/or clinical conditions.
Methods From July 2004 to May 2009, 1,300 patients underwent CAS using PEO. Patients received an independent neu-
rological assessment before the procedure and 1 h, 24 h, and 30 days after the procedure.
Results Procedural success was achieved in 99.7% of patients. In hospital, major adverse cardiac or cerebrovascular
events included 5 deaths (0.38%), 6 major strokes (0.46%), 5 minor strokes (0.38%), and no acute myocardial
infarction. At 30 days of follow-up, 2 additional patients died (0.15%), and 1 patient had a minor stroke (0.07%).
The 30-day stroke and death incidence was 1.38% (n  19). Symptomatic patients presented a higher 30-day
stroke and death incidence when compared with asymptomatic patients (3.04% vs. 0.82%; p  0.05). No signifi-
cant difference in 30-day stroke and death rate was observed between patients at high (1.88%; n  12) and
average surgical risk (1.07; n  7) (p  NS). Operator experience, symptomatic status, and hypertension were
found to be independent predictors of adverse events.
Conclusions The use of PEO for CAS is safe and effective in an unselected patient population. Anatomical and/or clinical con-
ditions of high surgical risk were not associated with an increased rate of adverse events. (J Am Coll Cardiol
2010;55:1661–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.079m
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parotid artery stenting (CAS) is considered to be a reason-
ble alternative to carotid endarterectomy (CEA), particu-
arly in patients at high risk for CEA (1). Although there are
o randomized studies comparing CAS with and without
mbolic protection devices (EPDs), consensus among ex-
erts suggests their use in reducing the risk of stroke during
AS (2). Among the EPDs that are in clinical use, proximal
PDs have the theoretical advantage of providing embolic
rotection during all phases of the intervention (2).
It has been reported that the use of proximal endovascular
cclusion (PEO) during CAS, as a proximal EPD, is
ssociated with a reduced amount of Doppler-detected
rom the Invasive Cardiology Laboratory, Cardiology Division, Clinica Montev-
rgine, Via Mario Malzoni 1, Mercogliano, Italy. Dr. Biamino was a scientific
onsultant for Invatec Spl (Italy), and does proctoring for Mo.Ma Systems. The
uthors want to dedicate this manuscript to the memory of Prof. Massimo Chiarello.i
Manuscript received July 4, 2009; revised manuscript received November 2, 2009,
ccepted November 2, 2009.icroembolic signals when compared with distal protection
evices (3). In multicenter registries, the use of PEO for
AS has been demonstrated to be safe and efficient in
elected patient populations (4–7). This registry presents
he results of a single-center experience on the use of PEO
or CAS in 1,300 patients.
ethods
atient selection. From July 2004 toMay 2009, 1,437 patients
nderwent CAS at our institution. Of these, 1,300 CAS proce-
ures were performed using PEO for neuroprotection.
See page 1668
Among the PEO-protected CAS procedures, 89 were
erformed from July 2004 to December 2004 in selected
atients (59.8% of a total of 149 CAS procedures performed
n the same period of time), and 1,211 were performed from
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secutive patients (93.9% of a total
of 1,288 CAS procedures per-
formed in the same period of
time). From July 2004 to De-
cember 2004, patients were se-
lected for PEO only if they did
not present with contralateral in-
ternal carotid artery occlusion/
stenosis or any stenosis of the
ipsilateral external carotid artery.
PEO was used from January
2005 to May 2009 in all consec-
utive patients undergoing CAS.
Inclusion criteria were the de-
gree of internal carotid artery
(ICA) stenosis, determined by
angiography, according to North
American Symptomatic Carotid
Endarterectomy Trial Criteria
(8,9): 1) asymptomatic stenosis
80%; and 2) symptomatic ste-
osis 50%. Symptomatic is defined as carotid stenosis
ssociated, within 6 months before the procedure, with
maurosis fugax, ipsilateral hemispheric transient ischemic
ttack, or ipsilateral ischemic stroke not resulting in a major
esidual neurological deficit (stroke scales: Barthel 60, Na-
ional Institutes of Health 15, or Rankin 3).
Patients with the following criteria were excluded:
) presence of a critical stenosis of the ipsilateral common
arotid artery (CCA); 2) occlusion of ipsilateral external
arotid artery (ECA); 3) an international normalized ratio
1.3; 4) contraindication to aspirin and thienopyridines;
nd 5) refused informed consent before enrollment.
oncomitant therapy. All patients received aspirin (75 to
60 mg/day) and should have been on ticlopidine (250 mg
wice daily) for at least 7 days. Alternatively, patients
eceived clopidogrel preload (300 mg) 24 h before the
rocedure. After the procedure, thienopyridines were con-
inued for 3 months, whereas aspirin was continued for life.
For anticoagulation, 70 to 100 IU/kg of heparin was
dministered before wiring the ECA, with intention to
chieve activated clotting time (ACT) 250 s. Additional
eparin was administered at operator discretion according
o ACT values (2). Forty-five patients received 0.75 mg/kg
f bivalirudin as intravenous bolus (Angiomax, The Medi-
ines Company, New York, New York) followed by infu-
ion at a rate of 2.5 mg/kg/h, discontinued at the end of the
rocedure (8).
echnique of the CAS procedure. All procedures were
erformed percutaneously, with the patient under local
nesthesia. The physicians performing the procedures ful-
lled reported qualification for training (10). Institutional
xperience was considered level 1 for the first 50 cases, level
for the following 250 cases, and level 3 for the remaining
Abbreviations
and Acronyms
ACT  activated clotting
time
CAS  carotid artery
stenting
CCA  common carotid
artery
CEA  carotid
endarterectomy
CI  confidence interval
ECA  external carotid
artery
EPD  embolic protection
device
ICA  internal carotid
artery
OR  odds ratio
PEO  proximal
endovascular occlusion,000 cases. nAt the start of the procedure, an 8 to 10 F, 25-cm long,
ntroducer sheath (Terumo, Tokyo, Japan) was inserted in
he infrarenal aorta via the common femoral artery. Coro-
ary angiography was performed in all patients before CAS
ue to the high incidence of concomitant coronary artery
isease (1). Presence of at least one 70% angiographic
oronary artery stenosis was considered as significant coro-
ary artery disease.
After aortic arch angiography, a selective bilateral carotid
rtery catheterization was performed using a 5-F JR4
iagnostic catheter advanced over a 0.035-inch soft hydro-
hilic wire (Standard Glidewire, Terumo).
Once diagnostic angiography was completed, the wire
as advanced in one of the ECA distal branches, the
iagnostic catheter was advanced in the distal ECA, and
hen the hydrophilic wire was exchanged for a 300-cm,
.035-inch stiff wire (Hi-Torque Supracore, Abbott Vascu-
ar, Abbott Park, Illinois). The Mo.Ma system (Invatec,
oncadelle, Italy) was guided over the stiff wire until the
adiopaque marker of the distal balloon was located in the
CA, at approximately 1 cm beyond bifurcation and in
roximity to or at the superior thyroidal artery (3). Then the
istal balloon was inflated in the ECA and the proximal
alloon in the CCA, thus blocking the antegrade and the
etrograde flow across the target vessel. A 0.014-inch wire
as then navigated through the ICA stenosis. Lesion
re-dilation was left to the operator’s discretion, and self-
xpanding carotid stents were deployed. Stents were classi-
ed according to alloy: nitinol or stainless steel (Carotid
allstent, Boston Scientific, Natick, Massachusetts). Niti-
ol stents were divided according to cell design: 1) closed
X-Act, Abbott Vascular); 2) open (Precise, Cordis, Miami,
lorida; Acculink, Abbott Vascular); and 3) hybrid, with closed
ells in the center and open at the sides (Cristallo Ideale,
nvatec) (11).
After dilation, at least 60 ml of blood was aspirated and
ltered through sieves, checking for visible plaque debris.
lood flow was restored only after 3 consecutive aspirations
ree of debris, deflating first the distal balloon and then the
roximal balloon. The final angiography included ipsilateral
iplane carotid and intracranial views (4–7).
ost-procedural patient management. Femoral sheaths
ere removed when ACT was 150 s in the heparin group
nd 2 h after the procedure, independently of ACT values,
n the bivaluridin group (12).
Access site hemostasis was achieved by manual compres-
ion in all patients. If clinical signs of limb ischemia
ccurred on the side of femoral access, sheaths were re-
oved independently of post-procedural time and ACT
alues. Femoral sheath-induced leg ischemia was classified
s major if it required thromboembolectomy and minor if it
esolved by sheath removal (13).
A complete blood count was obtained before the CAS
rocedure and before hospital discharge. An independent
eurologist assessed all patients (13).
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efined as the time from the inflation to the deflation of the
roximal balloon in the CCA. Occlusion intolerance was
efined as any transient neurological deficit observed during
cclusion time, but showing a complete recovery within 20
in after restoring antegrade flow. Procedural time was
efined as the time from the completion of diagnostic
ngiography and final intracranial views (4–7). Device
uccess was defined as the ability to position, deploy, and
etrieve the intact Mo.Ma device during the index proce-
ure (5). Protection success was defined as complete block-
de of antegrade blood flow in the ICA throughout the
ntire procedure (5). Technical success was defined as device
uccess and the ability to successfully implant a carotid stent
ith a residual ICA stenosis 30% (5). Procedural success
as defined as technical success without the occurrence of
ny major adverse cardiac or cerebrovascular event or unre-
olved occlusion intolerance during the index procedure.
The primary end point of the study was the incidence of
eath and any stroke in-hospital and at 30 days.
Neurological complications were classified as one of the
ollowing: 1) minor stroke, defined as a new neurological
eficit that either resolves completely within 30 days or
ncreased National Institute of Health Stroke Scale by 3;
nd 2) major stroke, defined as a new neurological deficit
hat persists for 30 days and increased National Institute
f Health Stroke Scale by 4 (1,14,15).
Patients were considered at high surgical risk if present-
ng with at least 1 or more high-risk criteria in either
edical comorbidities (age 80 years; Canadian Cardio-
ascular Society angina class III or IV or unstable angina;
ongestive heart failure class III or IV; left ventricular
jection fraction 30%; left main and/or 2-vessel coro-
ary; urgent [30 days] heart surgery; recent myocardial
nfarction [30 days]; severe chronic lung disease; severe
enal disease) or anatomical criteria (high cervical lesion;
atient Demographic CharacteristicsTable 1 Patient Demographic Characteristics
Male 71.5 (930)
Age (yrs) 69.9 7.6
High surgical risk 49.8 (648)
Anatomical criteria 7.9 (135)
Medical comorbidities 79.2 (597)
Both anatomical and medical 12.9 (84)
Age 80 yrs 9.3 (121)
Smoking history 69.6 (904)
Diabetes 24.6 (319)
Hypertension 88.9 (1,156)
LDL 100 mg/dl 76.2 (991)
History of CAD 35.4 (460)
Presence of significant CAD 66.0 (857)
Symptomatic patients 27.8 (361)
ate presented as % (n) or mean  SD.
CAD  coronary artery disease; LDL  low-density lipoprotein.esion below clavicle, prior radical neck surgery or radiation;
DEA restenosis; contralateral carotid occlusion; tracheos-
omy; contralateral laryngeal nerve palsy) (2).
ollow-up. All patients received a follow-up visit at 1
onth. Clinical examination assessed overall general con-
itions, neurological signs and symptoms, medications,
ospitalizations, or any type of complication that occurred
fter the procedure (13).
tatistics. Nominal and categorical variables were pre-
ented as contingency tables with frequencies and percent-
ges. Continuous variables were reported as the mean with
D and compared by t test for normally distributed values
p  0.05 was considered statistically significant). Propor-
ions were compared by chi-square or Fisher exact tests. A
-tailed p value 0.05 was considered statistically signifi-
ant for superiority analysis, and a 1-tailed p value 0.05
as considered statistically significant for noninferiority
nalysis. Through the program SPSS version 16.1 (SPSS
nc., Chicago, Illinois), we built a general linear model using
he 9 outcomes as logistic binary variables and all the
ollowing variables as the predictors: experience level, high
urgical risk, sex, age 80 years, smoking history, hyper-
ension, diabetes, low-density lipoprotein 100 mg, critical
tenosis of the ipsilateral external carotid artery, symptom-
tic status, and type of stent design (16).
esults
atient demographic characteristics are presented in Table 1. The
ast majority of patients were male, with a robust incidence
f atherosclerosis risk factors. Concomitant coronary artery
isease was present in 66.0% of the patients. Age 80 years
as relatively frequent (9.3%), and almost 50% of patients
ere at high surgical risk (2). Almost one-quarter of the
atients were symptomatic.
rocedural CharacteristicsTable 2 Procedural Characteristics
Contralateral ICA stenosis 70% 8.2 (107)
Contralateral ICA occlusion 4.3 (56)
Ipsilateral ECA stenosis 70% 7.2 (93)
Type of stent
Stainless steel 1.85 (24)
Open cells, nitinol 58.70 (763)
Closed cells, nitinol 5.23 (68)
Hybrid cells, nitinol 34.22 (445)
Pre-dilation 68.9 (896)
Post-dilation 100 (1,300)
Procedural time (min) 17.4 7.8
Occlusion time (s) 198 59
Occlusion intolerance 19.9 (257)
Immediate intolerance 0.3 (4)
Mo.Ma size (F)
10 42.5 (553)
9 26.6 (346)
8 30.8 (401)ate presented as % (n) or mean  SD.
ECA  external carotid artery; ICA  internal carotid artery.
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evere contralateral disease was present in 12.5% of patients,
nd in 56 patients (4.6% of total), the contralateral ICA was
ccluded.
Table 2 indicates the use of different types of stent. In
articular, stainless steel stents were used in 24 patients
1.8%), stents with open-cell design were used in 763
atients (58.7%), and stents with hybrid-cell design were
sed in 445 patients (34.2%).
Protection success was achieved in 99.7% of patients (n
,296). There was no difficulty in removing the deflated
istal balloon from underneath the stent struts.
In 4 cases (0.3%), patients showed immediate intolerance
o balloon occlusion. In 2 cases (0.15%), we decided to
eflate the proximal balloon and use the Mo.Ma system as
guiding catheter. Briefly, the Mo.Ma was left in place with
nly the distal balloon inflated, and a filter was advanced in
he internal carotid artery through the Mo.Ma working
hannel. Once the filter device was correctly placed distally
o the lesion, stenting was completed under distal protec-
ion. In the other 2 patients (0.15%), the procedure was
ompleted using the intermittent occlusion technique; the
cclusion balloons were deflated and blood aspirated after
ach procedural step (pre-dilation, stent release, and post-
ilation). In all these patients, procedural success was
chieved, and none experienced any adverse events.
In no cases were the ECA or CCA diameters large
nough that blood flow could not be blocked completely. In
.2% of the cases, a critical stenosis of the ipsilateral ECA
as present, but this did not preclude procedural success. In
he presence of significant stenosis of the ECA, the balloon
as inflated distal to the lesion.
The average time of endovascular occlusion was 198 
9 s (range 94 to 845 s).
Occlusion intolerance was observed in 257 patients
19.9%); in all cases, CAS could be concluded under
erebral protection. Despite the fact that 12.5% of the
atients had a total occlusion or a critical stenosis of the
ontralateral ICA, the presence of this anatomical condition
id not preclude protection success.
In most of these cases, symptoms of occlusion intolerance
tarted after stent post-dilation, during blood aspiration. The
verage back pressure of the group of patients presenting with
cclusion intolerance was lower than the corresponding
atients tolerant to occlusion (42.9  13.2 mm Hg vs. 66.0
14.0 mm Hg; p  0.001). Despite this, neurological
ymptoms resolved in each case within 20 min after resto-
ation of the antegrade blood flow.
Filtered blood showed the presence of visible atheroscle-
otic debris in 33.4% of patients.
Technical and procedural success was achieved in all
atients (100%). The primary end point occurred in 18
atients (1.38%) (Table 3).
During in-hospital stay, 2 patients died due to cardiovascu-
ar reasons: 1 patient had a pulmonary edema 4 h after the
rocedure and died due to ventricular fibrillation, and the other tatient experienced cardiac arrest the day after the procedure.
his patient had an acute coronary syndrome 4 h after the
rocedure because of an acute occlusion of the left anterior
escending artery that was treated with a percutaneous coro-
ary intervention. Unfortunately, because of a concomitant
evere aortic stenosis (for which he was scheduled for
ranscatheter aortic valve implantation) and compromised
eft ventricular function, the patient died the day after.
One patient died due to a hemorrhagic stroke that
ccurred 4 h after the procedure. Another 2 patients died
ue to noncardiovascular reasons: 1 because of multiorgan
ailure triggered by post-procedural acute renal failure and 1
ecause of subarachnoid bleeding probably caused by anti-
oagulation. During in-hospital stay, 5 patients had a minor
troke and 6 patients had a major, nonfatal stroke. The
umulative in-hospital incidence of death and stroke was
.15%.
During the 30-day follow-up period, 2 additional patients
ied. One patient died due to a drug-resistant pneumonia,
nd the other patient died due to a contrast-induced
ephropathy that resulted in acute renal failure.
During the 30-day follow-up period, 1 additional patient
ad a minor stroke; the patient presented with transient
onocular blindness, and a computed tomography scan
howed the presence of a new ischemic lesion in the visual
ortex. Symptoms disappeared by the 30-day follow-up
isit.
The incidence of events was higher in symptomatic
atients than in asymptomatic patients (3.0% vs. 0.8%; p 
.01). No difference was observed between patients with
1.78%) and without (1.44%) contralateral carotid artery
cclusion (p  NS). The incidence of events was higher in
atients at high surgical risk than in those at average surgical
isk (1.85% vs. 1.07%; p  0.05). No significant differences
ere observed among patients having anatomical criteria or
edical comorbidities, or both, of high surgical risk (Fig. 1).
The general linear model showed that independent pre-
ictors of events were level of institutional experience and
ymptomatic status, both in hospital and at 30 days of
ollow-up. From level 1 to 3 of institutional experience, the
n-hospital death and stroke incidence progressively de-
reased (level 1: 4%; level 2: 1.5%; level 3: 1.0%); 30-day
troke and death incidence similarly decreased (level 1: 4%;
evel 2: 1.5%; level 3: 1.2%). The higher the experience level,
eurological Complications and Deathsithin 30 Days After Caroti StentingTable 3 Neurological Complications and DeathsWithin 30 Days After Carotid Stenting
In Hospital
Discharge to
30-Day Follow-Up
Cumulative
30-Day
Minor strokes 5 (0.38) 1 (0.07) 6 (0.46)
Major strokes 6 (0.46) 0 (0.0) 6 (0.46)
Death 5 (0.38) 2 (0.15) 7 (0.61)
All nonfatal strokes 10 (0.76) 1 (0.07) 11 (0.84)
Death/strokes 16 (1.15) 3 (0.23) 19 (1.38)
alues are n (%).he lower the risk of in-hospital stroke (odds ratio [OR]:
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nd death and stroke (OR: 0.28; 95% CI: 0.14 to 0.59; p 
.01) (Fig. 2); the effect is similar of institutional experience
n cumulative (in-hospital plus 0 to 30 days) incidence of
troke (OR: 0.30; 95% CI: 0.13 to 0.67; p  0.01), death
OR: 0.30; 95% CI: 0.11 to 0.82; p  0.05), and death and
troke (OR: 0.30; 95% CI: 0.16 to 0.67; p  0.01) (Fig. 2).
Asymptomatic patients had a lower risk of in-hospital
OR: 4.25; 95% CI: 1.28 to 14.09; p  0.05) and 30-day
troke (OR: 2.32; 95% CI: 1.73 to 17.97; p  0.01).
imilarly, asymptomatic patients had a lower risk of in-
ospital cumulative events (OR: 3.56; 95% CI: 1.23 to
0.27; p  0.05) and 30-day cumulative events (OR: 1.52;
5% CI: 0.33 to 6.28; p  0.01) (Fig. 2).
Hypertensive condition (concomitant antihypertension
edications or blood pressure 140/90 mm Hg at hospital
dmission) was also shown to be an independent predictor
f 30-day stroke (OR: 0.27; 95% CI: 0.08 to 0.91; p  0.05)
nd death and stroke (OR: 0.34; 95% CI: 0.12 to 0.94; p 
.05) (Fig. 2).
In all patients, access site hemostasis was obtained by
anual compression. Despite the use of 8- to 10-F intro-
ucer sheaths, only 1 patient required a femoral percutane-
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Figure 1 Bar Graph Representing the 30-Day Stroke and Death
According to (A) symptomatic status, (B) age 80 or 80 years, (C) severity of surg
of high surgical risk for CEA (*p  0.05; #p  NS). Symptomatic patients andus transluminal angioplasty for an occlusive dissection. The dverall incidence of femoral artery pseudoaneurysm was
.3%; all were managed by manual compression. Surgical
epair of a pseudoaneurysm or blood transfusions were never
ecessary.
iscussion
he results of this registry confirm that PEO is a safe and
ffective neuroprotection system during CAS. It allowed us
o obtain an excellent rate of procedural success with a low
ncidence of death and stroke at 30 days, both in selective
nd consecutive patients. Even the presence of historical
natomical contraindications to PEO use (i.e., contralateral
cclusions) did not increase incidence of post-procedural
vents. Patients at high surgical risk had a greater incidence
f events, even though this condition was not an indepen-
ent events predictor in the general linear model.
In this registry, the PEO, which combines the functions of
working sheath and cerebral protection in a single system,
as successfully positioned in all patients. Only 19.1% of
atients were intolerant to blood flow arrest. The incidence of
cclusion intolerance in this registry is higher than the range
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Endovascular Occlusion for Neuroprotected Coronary Artery Stenosis April 20, 2010:1661–7dentified, but it could be related to the robust presence of
atients with contralateral carotid artery occlusion, the elevated
umber of patients with age 80 years, and the significant
resence of medical comorbidities. However, occlusion intol-
rance did not interfere with procedural success.
In 2 cases, because of the immediate onset of occlusion
ntolerance, we had to use a distal filter through the sheath
f the Mo.Ma device, thus confirming that the PEO does
ot preclude the use of alternative or adjunctive methods of
istal protection (7). In the other 2 cases of immediate
ntolerance, we adopted the intermittent occlusion tech-
ique. Adverse events were not observed in these 4 patients.
herefore, intolerance to proximal protection systems can
asily be overcome in order to obtain a successful and
protected” stent procedure without complications.
There were no device-related complications at the bal-
oon inflation sites or difficulties in retrieving the device
ith deflated balloons. Despite the use of 8- to 10-F
heaths, the incidence of access site complications in the
resent registry was low (2.3%); percutaneous transluminal
In Hospital Stroke
0.01
0.10
1.00
10.00
100.00
In Hospital Death
0 .01
0 .10
1.00
10 .00
100 .00
0.01
1
0.10
1.00
10.00
100.00
A
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2 3 4 5 6 7 8 9 10 11
Figure 2 General Linear Model of Predictors for In-Hospital and
(A) In-hospital stroke; (B) in-hospital death; (C) in-hospital death and stroke; (D)
red circles, p  0.05). X-axis legend: 1  stent design; 2  experience level; 3  oc
8  diabetes; 9  low-density lipoprotein 100 mg/dl; 10  symptomatic; 11 
 proximal endovascular occlusion.ngioplasty of the femoral artery was necessary only in 1 case w0.09 %), and in no case was surgical repair or blood
ransfusion required.
Described limitations of proximal protection devices are
he presence of a critical stenosis or extremely large diameter
f the ECA. In this study, the presence of a critical stenosis
f the ECA did not preclude procedural success, and in no
ases was a pre-dilation of the ECA necessary. Moreover,
he presence of a critical ECA stenosis was not associated
ith higher post-procedural events. In no cases was the
CA diameter so large that blood flow could not be arrested
fter distal balloon inflation.
In contrast to reported multicenter studies, patients with
ontralateral ICA occlusion were not excluded from the
tudy. This anatomical condition did not preclude proce-
ural success and did not increase incidence of events both
n-hospital and at 30 days of follow-up.
The observed in-hospital stroke/death rate (1.15%) (Table
) confirmed the efficacy and safety of PEO. The origin of the
mbolic events leading to ischemic strokes, all documented by
omputed tomography, is uncertain. In all cases, the evaluation
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April 20, 2010:1661–7 Endovascular Occlusion for Neuroprotected Coronary Artery StenosisThe 1.38% 30-day stroke/death rate in the present
egistry is comparable to that of other studies evaluating
AS with endovascular occlusion. The incidence of events
ccording to symptomatic status is well below the limits set
y guidelines (2).
Worthy of mention is the fact that the general linear
odel showed that level of institutional experience, symp-
omatic status, and hypertension are the only predictors for
ost-procedural events. Despite the fact that the operators
ulfilled the appropriate criteria of training (10), the higher
he institutional experience with PEO use, the lower is the
isk of events. The hypertensive status showed to be a
egative predictor of 30-day events. The clinical significance
f this protective effect requires further investigation.
Finally, it must be noted that the present study included
first group of patients who are selected according to
vailable inclusion and exclusion criteria and a second group
f consecutively treated patients. The outcome of these 2
roups is similar, thus demonstrating that PEO can suc-
essfully be applied during CAS in the vast majority of
atients.
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